Insider Selling: United Therapeutics Co. (NASDAQ:UTHR) CEO Sells $2,092,000.00 in Stock

United Therapeutics Co. (NASDAQ:UTHR – Get Rating) CEO Martine A. Rothblatt sold 8,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 31st. The shares were sold at an average price of $261.50, for a total transaction of $2,092,000.00. Following the completion of the transaction, the chief executive officer now owns 130 shares of the company’s stock, valued at $33,995. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

United Therapeutics Stock Performance

NASDAQ:UTHR opened at $252.80 on Friday. The stock has a market cap of $11.52 billion, a P/E ratio of 17.20, a price-to-earnings-growth ratio of 1.85 and a beta of 0.63. The firm’s fifty day simple moving average is $270.06 and its 200 day simple moving average is $242.68. United Therapeutics Co. has a twelve month low of $158.38 and a twelve month high of $283.09. The company has a quick ratio of 9.39, a current ratio of 9.68 and a debt-to-equity ratio of 0.18.

United Therapeutics (NASDAQ:UTHR – Get Rating) last released its quarterly earnings results on Wednesday, November 2nd. The biotechnology company reported $4.91 earnings per share for the quarter, beating the consensus estimate of $3.57 by $1.34. The business had revenue of $516.00 million for the quarter, compared to analysts’ expectations of $492.92 million. United Therapeutics had a net margin of 38.03% and a return on equity of 16.63%. As a group, research analysts predict that United Therapeutics Co. will post 16.58 EPS for the current year.

Institutional Trading of United Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Calamos Advisors LLC bought a new stake in United Therapeutics in the second quarter valued at $525,000. UMB Bank n.a. boosted its holdings in shares of United Therapeutics by 91.8% during the 2nd quarter. UMB Bank n.a. now owns 1,306 shares of the biotechnology company’s stock valued at $308,000 after buying an additional 625 shares in the last quarter. DekaBank Deutsche Girozentrale boosted its holdings in shares of United Therapeutics by 0.4% during the 3rd quarter. DekaBank Deutsche Girozentrale now owns 26,081 shares of the biotechnology company’s stock valued at $5,362,000 after buying an additional 92 shares in the last quarter. Hallmark Capital Management Inc. bought a new stake in shares of United Therapeutics during the 2nd quarter valued at $33,000. Finally, Roman Butler Fullerton & Co. bought a new stake in shares of United Therapeutics during the 2nd quarter valued at $1,573,000. Institutional investors own 95.63% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on UTHR. UBS Group began coverage on shares of United Therapeutics in a research report on Tuesday, December 6th. They issued a “buy” rating and a $320.00 price objective for the company. Argus lifted their target price on shares of United Therapeutics from $250.00 to $300.00 and gave the company a “buy” rating in a research report on Wednesday, January 11th. Morgan Stanley lifted their target price on shares of United Therapeutics from $322.00 to $330.00 and gave the company an “overweight” rating in a research report on Tuesday, December 6th. Wedbush lifted their target price on shares of United Therapeutics from $250.00 to $305.00 in a research report on Thursday, November 3rd. Finally, Oppenheimer lifted their target price on shares of United Therapeutics from $325.00 to $375.00 and gave the company an “outperform” rating in a research report on Thursday, November 3rd. Two analysts have rated the stock with a sell rating, one has assigned a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $283.64.

United Therapeutics Company Profile

(Get Rating)

United Therapeutics Corp. operates as a biotechnology company engaged in the development and commercialization of products for patients with chronic and life-threatening diseases. The firm markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. It is involved in the development of novel pharmaceutical therapies and technologies that expand the availability of transplantable organs.